FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
20 letters match. Newest first.
-
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsTentamus India Private Limited
FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.
High risk -
DrugsRhyz Analytical Labs
FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.
High risk -
DrugsBRS Analytical Services, LLC
BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.
High risk -
DrugsChromatography Institute of America dba Compounder’s International Analytical Laboratory
FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.
High risk -
DrugsShiva Analyticals Private Limited
FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
High risk -
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsCenter for Instrumental Analysis of China Pharmaceutical University
Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.
High risk -
DrugsAnalytical Food Laboratories, Inc.
FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.
High risk -
DrugsGrupo Quimico SRL
FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.
High risk -
DrugsCohere Beauty
FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.
Medium -
DrugsSure-Biochem Laboratories, LLC
FDA says contract lab Sure-Biochem missed Burkholderia cepacia in drug samples and cites broad CGMP failures.
High risk -
DrugsGreen Wave Analytical, LLC
FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.
High risk -
DrugsMiami University Department of Chemistry and Biochemistry
Miami University contract testing lab falsified heparin API test data and lacked CGMP controls.
High risk -
DrugsThe W.S. Badger Company, Inc.
FDA warned W.S. Badger over repeat manufacturing-quality failures in OTC drug products, including sunscreen process, cleaning, test-method, and OOS investigation problems.
High risk -
DrugsVitae Enim Vitae Scientific Inc.
FDA warned Vitae Enim Vitae Scientific of sterile drug CGMP violations and contamination-control failures after a 2021 inspection, leading to a recall.
High risk -
DrugsAccu Bio-Chem Laboratories
FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.
Medium -
DrugsMissouri Analytical Laboratories Inc
Missouri Analytical Laboratories, a contract drug testing lab, cited for manufacturing practice violations including inadequate out-of-specification investigations and data integrity failures.
High risk